Literature DB >> 1775157

Biopterin conversion to reduced folates by Leishmania donovani promastigotes.

J T Beck1, B Ullman.   

Abstract

The ability of Leishmania donovani promastigotes to proliferate in folate-deficient medium supplemented with pterins suggests that pterins can serve as a source of folate in these parasites [16]. Using reversed-phase high-performance liquid chromatography, the ability of intact L. donovani to transform [3H]biopterin into tetrahydrofolates was demonstrated. Radioactivity was primarily associated with 5-methyltetrahydrofolate and 10-formyltetrahydrofolate. A mutant strain of L. donovani, MTXA5, that was genetically deficient in folate transport capacity and incapable of growing in pterin-supplemented folate-deficient growth medium, exhibited a greatly reduced capacity to metabolize [3H]biopterin to reduced folates. These data indicated that wild-type L. donovani promastigotes, unlike mammalian cells, were able to convert biopterin to tetrahydrofolates and supported the hypothesis that folate transport deficiency in mutant organisms is associated with an inability to transform pterins to reduced folates.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1775157     DOI: 10.1016/0166-6851(91)90126-q

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  10 in total

1.  Increased transport of pteridines compensates for mutations in the high affinity folate transporter and contributes to methotrexate resistance in the protozoan parasite Leishmania tarentolae.

Authors:  C Kündig; A Haimeur; D Légaré; B Papadopoulou; M Ouellette
Journal:  EMBO J       Date:  1999-05-04       Impact factor: 11.598

2.  Molecular cloning, expression and enzymatic assay of pteridine reductase 1 from Iranian lizard Leishmania.

Authors:  Bahram Kazemi; Farideh Tohidi; Mojgan Bandehpour; Fatemeh Yarian
Journal:  Iran Biomed J       Date:  2010-07

3.  Functional identification of orthologous genes encoding pterin recycling activity in Plasmodium falciparum and Toxoplasma gondii.

Authors:  Qi Wang; Vicia Hauser; Martin Read; Ping Wang; Andrew D Hanson; Paul F G Sims; John E Hyde
Journal:  Mol Biochem Parasitol       Date:  2005-11-28       Impact factor: 1.759

Review 4.  Folate metabolic pathways in Leishmania.

Authors:  Tim J Vickers; Stephen M Beverley
Journal:  Essays Biochem       Date:  2011       Impact factor: 8.000

5.  PTR1: a reductase mediating salvage of oxidized pteridines and methotrexate resistance in the protozoan parasite Leishmania major.

Authors:  A R Bello; B Nare; D Freedman; L Hardy; S M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

6.  Plasticity in chromosome number and testing of essential genes in Leishmania by targeting.

Authors:  A K Cruz; R Titus; S M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

7.  Glucantime susceptibility of Leishmania promastigotes under variable growth conditions.

Authors:  E S Moreira; R M Soares; M de L Petrillo-Peixoto
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

Review 8.  Reproduction in Trypanosomatids: Past and Present.

Authors:  Camino Gutiérrez-Corbo; Bárbara Domínguez-Asenjo; María Martínez-Valladares; Yolanda Pérez-Pertejo; Carlos García-Estrada; Rafael Balaña-Fouce; Rosa M Reguera
Journal:  Biology (Basel)       Date:  2021-05-27

9.  Inhibition of Leishmania major PTR1 Gene Expression by Antisense in Escherichia coli.

Authors:  F Kheirandish; M Bandehpour; A Haghighi; F Mahboudi; M Mohebali; B Kazemi
Journal:  Iran J Public Health       Date:  2012-06-30       Impact factor: 1.429

10.  Gene regulation of pteridine reductase 1 in leishmania promastigotes and amastigotes using a full-length antisense construct.

Authors:  F Kheirandish; M Bandehpour; N Davoudi; N Mosaffa; S Dawood; B Kazemi; A Haghighi; A Khamesipour; H Masjedi; M Mohebali; F Mahboudi
Journal:  Iran J Parasitol       Date:  2013-04       Impact factor: 1.012

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.